CDC144A: A Potential Drug Target and Biomarker for Cancer (G9720)

Target Name: CCDC144A

NCBI ID: G9720

CCDC144A

CDC144A: A Potential Drug Target and Biomarker for Cancer

CCDC144A, also known as C144A_HUMAN, is a protein that is expressed in various tissues of the human body. It is a member of the carcinoembryonic antigen (CEA) family and is involved in the development and maintenance of tissues, including the skin, lung, liver, and pancreas.

CDC144A is a transmembrane protein that is expressed in the cytoplasm of cells. It is composed of four constant (C) regions and a variable (V) region that is unique to this protein. The C regions of CDC144A contain a conserved domain that is involved in cell signaling and are highly conserved across different species. The variable region of CDC144A contains a unique protein that is specific to this gene and is involved in cell signaling.

CDC144A is involved in a variety of physiological processes in the body, including cell signaling, embryonic development, and tissue growth. It is a key regulator of cell signaling pathways, including the TGF-β pathway. This pathway is involved in the development and maintenance of tissues and is a key factor in the development of cancer.

CDC144A has also been identified as a potential drug target. Studies have shown that inhibiting CDC144A can lead to the inhibition of cell signaling pathways that are involved in cancer development. This suggests that CDC144A may be a useful target for cancer therapies.

In addition to its potential as a drug target, CDC144A is also a potential biomarker. The C144A gene is widely expressed in various tissues of the human body and is often used as a marker for cancer diagnosis and prognosis. The expression of CDC144A has been shown to be associated with the development and progression of many types of cancer, including breast, lung, and ovarian cancer.

CDC144A is also involved in the development and maintenance of tissues, including the skin, lung, liver, and pancreas. It is a key regulator of cell signaling pathways, including the TGF-β pathway. This pathway is involved in the development and maintenance of tissues and is a key factor in the development of cancer.

In conclusion, CDC144A is a transmembrane protein that is involved in a variety of physiological processes in the body, including cell signaling and embryonic development. It is a key regulator of cell signaling pathways, including the TGF-β pathway, and has been identified as a potential drug target and biomarker. Further research is needed to fully understand the role of CDC144A in the development and progression of cancer.

Protein Name: Coiled-coil Domain Containing 144A

Functions: May play a role in preventing the formation of kidney stones through inhibition of calcium oxalate monohydrate (COM) crystallization, attenuating COM-induced apoptotic injury to renal epithelial cells (PubMed:32991878). May exhibit antilithiatic (preventing the formation of kidney stones) activity through crystal binding, hindering the crystal attachment to renal epithelial cells, a pre-requisite to initiate inflammatory response (PubMed:32991878)

The "CCDC144A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC144A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets